FrancophonIA/ELRC3.0 huggingface dataset:
English: • Serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Estonian: Väga harva esinevad kõrvaltoimed on rasked allergilised reaktsioonid, nagu nt ravimilööve koos eosinofiilia ja kogu organismi haaravate sümptomitega (DRESS-sündroom).
English: During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Estonian: Olansapiinravi kombineerimisel liitiumi või divalproeksiga täheldati akuutse ravi ajal (kuni 6 nädalat) 17,4 %-l patsientidest vähemalt 7 %-list kaalutõusu, võrreldes ravi algusega.
English: 10 As assessed by measured values from clinical trials in the Olanzapine Integrated Database.
Estonian: 10 Hinnatuna mõõdetud väärtusega kliinilistest uuringutest olansapiini ühendandmebaasis.
English: Elevated glucose levels4
Estonian: Glükoosisisalduse tõus4
English: • Carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepresant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Olanzapine Glenmark dose.
Estonian: või tsiprofloksatsiini (antibiootikum) - võib olla on vaja teie Olanzapine Glenmark annust korrigeerida.
English: Nervous system disorders Somnolence
Estonian: Närvisüsteemi häired Unisus
English: Olanzapine Glenmark contains the active substance olanzapine.
Estonian: Olanzapine Glenmark sisaldab toimeainet olansapiini.
English: Bradycardia QTc prolongation (see section 4.4)
Estonian: Bradükardia QTc intervalli pikenemine (vt lõik
English: METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use.
Estonian: MANUSTAMISVIIS JA -TEE Enne ravimi kasutamist lugege pakendi infolehte Suukaudne
English: You should swallow the Olanzapine Glenmark tablets whole, with water.
Estonian: Olanzapine Glenmark tablett tuleb tervelt alla neelata ning juua peale vett.
English: Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l - < 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
Estonian: Esialgse piiripealse tühja kõhu triglütseriidide taseme (≥ 1,69 mmol/l...< 2,26 mmol/l) muutumine kõrgeks (≥ 2,26 mmol/l) oli väga sage.
English: mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l< 1.467 mmol/l) to high (≥ 1.467 mmol/l).
Estonian: (≥ 1,467 mmol/l) ja esialgse piiripealse tühja kõhu triglütseriidide taseme (≥ 1,016 mmol/l< 1,467 mmol/l) muutumist kõrgeks (≥ 1,467 mmol/l).
English: In female versus male subjects the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hrs) and the clearance was reduced (18.9 versus 27.3 l/hr).
Estonian: Naistel oli meespatsientidega võrreldes keskmine eliminatsiooni poolväärtusaeg mõnevõrra pikenenud (36,7 versus 32,3 tundi) ja kliirens vähenenud (18,9 versus 27,3 l/t).
English: Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Estonian: Patsientidega, kellel on ALAT ja/või ASAT tõusnud, kellel esinevad maksakahjustuse sümptomid, kellel esinevad eelnevalt piiratud maksafunktsiooni reserviga seotud seisundid ning patsientidega, keda ravitakse potentsiaalselt hepatotoksiliste ravimitega, tuleb olla ettevaatlik ning neid tuleb jälgida.
English: In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5 % vs 1.5 %, respectively).
Estonian: Dementsusega seotud psühhoosi ja/või käitumishäiretega eakaid patsiente (keskmine vanus 78 aastat) hõlmanud platseebo-kontrollitud kliinilistes uuringutes (kestusega 6-12 nädalat) registreeriti olansapiiniga ravitud patsientidel kahekordset suremuse tõusu võrreldes platseeboga (3,5 % versus 1,5 % vastavalt).
English: Thromboembolis m (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
Estonian: Trombemboolia (sh kopsuarteri emboolia ja süvaveenide tromboos) (vt lõik
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE KUUPÄEV
English: Amnesia 9
Estonian: Amneesia9
English: - High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Olanzapine Glenmark.
Estonian: • Olanzapine Glenmark't kasutavatel patsientidel on täheldatud kõrge veresuhkru ja kõrge rasva tasemeid (triglütseriidid ja kolesterool).
English: This may be harmful for people with phenylketonuria.
Estonian: See võib olla kahjulik fenüülketonuuriaga inimestele.
English: - Weight gain has been seen in patients taking Olanzapine Glenmark.
Estonian: • Olanzapine Glenmark't kasutavatel patsientidel on täheldatud kaalutõusu.
English: Do not stop taking your tablets just because you feel better.
Estonian: Kui Te lõpetate Olanzapine Glenmark võtmise Ärge lõpetage tablettide kasutamist kohe, kui tunnete ennast paremini.
English: Olanzapine Glenmark belongs to a group of medicines called antipsychotics.
Estonian: Olanzapine Glenmark kuulub ravimite rühma,
English: Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Estonian: Vähestel koertel, keda raviti annustega 8 või 10 mg/kehakaalu kg/ööpäevas (tsirkuleeriva olansapiini koguhulk [AUC] on 12 kuni 15 korda suurem kui inimesel, kes on saanud 12 mg annuse), arenesid neutropeenia, trombotsütopeenia või aneemia, mis olid mööduvad.
English: Gastrointestinal disorders Mild, transient anticholinergic effects including constipation and dry mouth
Estonian: Seedetrakti häired Kerged, mööduvad antikoliinergilised toimed, sh. kõhukinnisus ja suukuivus.
English: Aluminium/aluminium blisters in cartons of 28, 35, 56, 70 and 98 tablets per carton.
Estonian: Alumiinium/alumiinium blistrid karpides, mis sisaldavad 28, 35, 56, 70, 98 tabletti.
English: Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Olanzapine Glenmark and regularly during treatment.
Estonian: Regulaarselt ravi ajal ning enne Olanzapine Glenmark võtmise alustamist peaks arst peaks teie veresuhkru ja teatud rasvade tasemeid vereanalüüside teel kontrollima.
English: Olanzapine Glenmark 7.5 mg: yellow coloured circular flat bevelled edge tablets with ‘C' debossed on one side.
Estonian: Olanzapine Glenmark 7,5 mg: kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „C”.
English: Gastrointestinal disorders Mild, transient anticholinergic effects including
Estonian: Seedetrakti häired Kerged, mööduvad antikoliinergilised toimed, sh.
English: MARKETING AUTHORISATION HOLDER Glenmark Arzneimittel GmbH Industriestr.
Estonian: Müügiloa hoidja Glenmark Arzneimittel GmbH Industriestr.
English: Systemic Symptoms (DRESS)
Estonian: Teadmata nismi haaravate sümptomitega (DRESSsündroom)
English: Olanzapine Glenmark contains a source of phenylalanine.
Estonian: Olanzapine Glenmark sisaldab fenüülalaniini allikat.
English: Aluminium/aluminium blisters in cartons of 28, 56, 70, 98 tablets per carton.
Estonian: Alumiinium/alumiinium blistrid karpides, mis sisaldavad 28, 56, 70, 98 tabletti.
English: There is a risk of feeling drowsy when you are given Olanzapine Glenmark.
Estonian: Olanzapine Glenmark kasutamise ajal võite end uimasena tunda.
English: Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17- < 6.2 mmol/l) to high (≥ 6.2 mmol/l) were very common.
Estonian: Esialgse piiripealse tühja kõhu üldkolesterooli taseme (≥ 5,17...< 6,2 mmol/l) muutumine kõrgeks (≥ 6,2 mmol/l) oli väga sage.
English: The pharmacokinetics of olanzapine are similar between adolescents and adults.
Estonian: Noorukid (vanuses 13-17 aastat): Olansapiini farmakokineetika noorukite ja täiskasvanute vahel on sarnane.
English: 5 Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high (≥ 2.26
Estonian: 5 Täheldati neil, kel esines esialgselt normaalne tase tühja kõhu seisundis (< 1,69 mmol/l), mis tõusis kõrgele (≥ 2,26 mmol/l).
English: How to store Olanzapine Glenmark
Estonian: Kuidas Olanzapine Glenmark`t säilitada
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON
Estonian: Lisainformatsiooni saamiseks vt pakendi infolehte
English: NAME OF THE MARKETING AUTHORISATION HOLDER Glenmark Arzneimittel GmbH
Estonian: MÜÜGILOA HOIDJA NIMI Glenmark Arzneimittel GmbH
English: It is important that you carry on taking Olanzapine Glenmark for as long as your doctor tells you.
Estonian: Tähtis on, et jätkaksite tablettide võtmist niikaua, kui arst seda nõuab.
English: May be harmful for people with phenylketonuria.
Estonian: Võib olla kahjulik fenüülketonuuriaga inimestele.
English: High creatine phosphokinase11
Estonian: Kreatiinfosfokinaasi aktiivsuse tõus11
English: Only take other medicines while you are on Olanzapine Glenmark if your doctor tells you that you can. You might feel drowsy if Olanzapine Glenmark is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
Estonian: Kui olete manustanud Olanzapine Glenmark't koos antidepressantidega või ärevust vähendavate ja und soodustavate ravimitega (trankvillisaatoritega), võite ennast unisena tunda.
English: Potential interactions affecting olanzapine
Estonian: Teiste ravimite potentsiaal mõjutada olansapiini toimet
English: In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p= 0.001) favouring olanzapine (- 6.0) versus haloperidol (- 3.1).
Estonian: Viidi läbi rahvusvaheline, topeltpime võrdlev uuring, milles vaadeldi 1481 patsienti skisofreenia, skisoafektiivsete ning nendega seotud häiretega, kellel kaasnesid mitmesuguse raskusastmega depressiooni sümptomid (keskmine punktisumma enne ravi oli 16,6 Montgomery-Asbergi depressiooniskaala järgi).
English: Olanzapine Glenmark 7.5 mg tablets
Estonian: Olanzapine Glenmark 7,5 mg tabletid
English: constipation and dry mouth
Estonian: Teadmata kõhukinnisus ja suukuivus.
English: What Olanzapine Glenmark contains - The active substance is olanzapine - Each Olanzapine Glenmark tablet contains 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg olanzapine
Estonian: Mida Olanzapine Glenmark sisaldab - Toimeaine on olansapiin - Üks Olanzapine Glenmark'i tablett sisaldab 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg või 20 mg olansapiini - Abiained on mannitool (E421), mikrokristalne tselluloos, aspartaam (E951), krospovidoon,
English: 14 Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (≥ 1.467
Estonian: 14 Vaadeldi esialgselt normaalset taset tühja kõhu seisundis (< 1,016 mmol/l), mis tõusis kõrgele
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 7.5 mg olanzapine.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga tablett sisaldab 7,5 mg olansapiini.
English: 3 Observed for fasting normal levels at baseline (< 5.17 mmol/l) which increased to high (≥ 6.2
Estonian: 3 Täheldati neil, kel esines esialgselt normaalne tase tühja kõhu seisundis (< 5,17 mmol/l), mis tõusis kõrgele (≥ 6,2 mmol/l).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 7.5 mg olanzapine.
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 7,5 mg olansapiini.
English: Olanzapine Glenmark 5 mg: yellow coloured circular flat bevelled edge tablets with ‘B' debossed on one side.
Estonian: Olanzapine Glenmark 5 mg: kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „B”.
English: Olanzapine Glenmark 10 mg tablets
Estonian: Olanzapine Glenmark 10 mg tabletid
English: Neuroleptic malignant syndrome (see section
Estonian: Maliigne neuroleptikumisünd -room (vt lõik 4.4)12
English: PHARMACEUTICAL FORM AND CONTENTS
Estonian: RAVIMVORM JA PAKENDI SUURUS Tablett
English: Olanzapine Glenmark 15 mg tablets
Estonian: Olanzapine Glenmark 15 mg tabletid
English: Increased alkaline phosphatase10
Estonian: Suurenenud alkaalne fosfataas10
English: Olanzapine Glenmark 2.5 mg tablets
Estonian: Olanzapine Glenmark 2,5 mg tabletid
English: Olanzapine Glenmark 20 mg: yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘F' debossed on other side.
Estonian: Olanzapine Glenmark 20 mg: kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „OL” ja teisele küljele on pressitud „F”.
English: 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 %of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
Estonian: (kg) väga sage (40,6 %), ≥ 15 % esialgsest kehakaalust oli sage (7,1 %) ja ≥ 25 % oli aeg-ajalt (2,5 %).
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg olanzapine.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga tablett sisaldab 10 mg olansapiini.
English: Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark unless your doctor tells you to.
Estonian: Olanzapine Glenmark ööpäevane annus on 5 mg ja 20 mg. Sümptomite taastumisel konsulteerige arstiga, kuid ärge katkestage Olanzapine Glenmark kasutamist ilma arsti korralduseta.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg olanzapine.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga tablett sisaldab 2,5 mg olansapiini.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 20 mg olanzapine
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 20 mg oolansapiini
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 15 mg olanzapine.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga tablett sisaldab 15 mg olansapiini.
English: In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki< 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5 α1 adrenergic; and histamine H1 receptors.
Estonian: Prekliinilistes uuringutes on olansapiinil ilmnenud hulk afiinsusi (Ki; < 100 nM) - serotoniini 5 HT2A/2C-, 5 HT3-, 5 HT6-, dopamiini D1-, D2-, D3-, D4-, D5-, koliinergiliste muskariini M1-M5, 1-adrenergiliste ja histamiini H1-retseptorite suhtes.
English: Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and < 0.1%) when olanzapine is stopped abruptly.
Estonian: Olansapiinravi järsul katkestamisel on harva ( ≥ 0,01% ja < 0,1%) registreeritud ägedaid sümptomeid nagu higistamine, unetus, treemor, ärevus, iiveldus või oksendamine.
English: Tablet Yellow coloured circular flat bevelled edge tablets with ‘C' debossed on one side.
Estonian: Kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „C”.
English: Olanzapine Glenmark 15 mg: yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘E' debossed on other side.
Estonian: Olanzapine Glenmark 15 mg: kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „OL” ja teisele küljele on pressitud „E”.
English: Excipient with known effect: Each tablet contains 0.23 mg of aspartame For the full list of excipients, see section 6.1.
Estonian: Teadaolevat toimet omavad abiained: Iga tablett sisaldab 0,23 mg aspartaami Abiainete täielik loetelu vt lõik 6.1.
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 7.5 mg tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 7,5 mg tabletid
English: High uric acid 10
Estonian: Kõrge kusihappetase10
English: 4.4)12Discontinuat ion symptoms7, 12
Estonian: Maliigne neuroleptikumisünd -room (vt lõik 4.4)12 Ravi katkestamise sümptomid7,12
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 20 mg tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 20 mg tabletid
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 2.5 mg tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 2,5 mg tabletid
English: Excipient with known effect: Each tablet contains 0.46 mg of aspartame For the full list of excipients, see section 6.1.
Estonian: Teadaolevat toimet omavad abiained: Iga tablett sisaldab 0,46 mg aspartaami Abiainete täielik loetelu vt lõik 6.1.
English: Dysarthria Stuttering11
Estonian: Tardiivdüskineesia1
English: Excipient with known effect: Each tablet contains 0.35 mg of aspartame For the full list of excipients, see section 6.1.
Estonian: Teadaolevat toimet omavad abiained: Iga tablett sisaldab 0,35 mg aspartaami Abiainete täielik loetelu vt lõik 6.1.
English: Olanzapine Glenmark 10 mg: yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘D' debossed on other side.
Estonian: Olanzapine Glenmark 10 mg: kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „OL” ja teisele küljele on pressitud „D”.
English: Excipient with known effect: Each tablet contains 0.69 mg of aspartame For the full list of excipients, see section 6.1.
Estonian: Teadaolevat toimet omavad abiained: Iga tablett sisaldab 0,69 mg aspartaami Abiainete täielik loetelu vt lõik 6.1.
English: Tablet Yellow coloured circular flat bevelled edge tablets with ‘A' debossed on one side.
Estonian: Kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „A”.
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 7.5 mg tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 7,5 mg tabletid Olanzapinum
English: • Stuttering
Estonian: • Krambid
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 10 mg tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 10 mg tabletid
English: Yellow coloured circular flat bevelled edge tablets with ‘B' debossed on one side.
Estonian: Kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „B”.
English: Yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘E' debossed on other side.
Estonian: Kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „OL” ja teisele küljele on pressitud „E”.
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 20 mg tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 20 mg tabletid Olanzapinum
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 15 mg tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 15 mg tabletid
English: Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Estonian: Tavaliselt, eriti ravi varajases faasis, on esinenud maksa aminotransferaaside ALAT ja ASAT aktiivsuse mööduvat, asümptomaatilist tõusu.
English: Warnings and precautions Talk to your doctor or pharmacist before you take Olanzapine Glenmark
Estonian: Enne Olanzapine Glenmark võtmist pidage nõu oma arsti või apteekriga.
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 2.5 mg tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 2,5 mg tabletid Olanzapinum
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 10 mg tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 10 mg tabletid Olanzapinum
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 15 mg tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 15 mg tabletid Olanzapinum
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 5 mg tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 5 mg tabletid
English: In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α 1 adrenergic; and histamine H1 receptors.
Estonian: Prekliinilistes uuringutes on olansapiinil ilmnenud hulk afiinsusi (Ki; < 100 nM) - serotoniini 5 HT2A/2C-, 5 HT3-, 5 HT6-, dopamiini D1-, D2-, D3-, D4-, D5-, koliinergiliste muskariini M1-M5, 1
English: If you stop taking Olanzapine Glenmark
Estonian: Ärge kasutage Olanzapine Glenmark't
English: • Sleepiness
Estonian: Neerukahjustus
English: Abdominal
Estonian: Fenüülalaniin
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 5 mg tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark 5 mg tabletid Olanzapinum
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg olanzapine Excipient with known effect: Each tablet contains 0.92 mg of aspartame For the full list of excipients, see section 6.1.
Estonian: Teadaolevat toimet omavad abiained Abiaine: Iga tablett sisaldab 0,92 mg aspartaami Abiainete täielik loetelu vt lõik 6.1.
English: • Prolonged and/or painful erection.
Estonian: Neeru- ja/või maksakahjustus
English: High Gamma Glutamyltransferase High uric acid 10
Estonian: Kreatiinfosfokinaasi aktiivsuse tõus11 Suurenenud gamma glutamüültransferaas i hulk10
English: Yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘D' debossed on other side.
Estonian: Kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „OL” ja teisele küljele on pressitud „D”.
English: Dizziness Akathisia6
Estonian: Pearinglus Akatiisia6
English: 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 %of baseline body weight was common (7.1 %) and ≥
Estonian: 13 Pärast lühiajalist ravi (keskmine kestus 22 päeva), oli kehakaalutõus ≥ 7 % esialgsest kehakaalust
English: Thromboembolis hypotension10
Estonian: Ortostaatiline hüpotensioon1
English: Breast feeding
Estonian: Kantserogeensus
English: Pancreatitis11
Estonian: Rabdomüolüüs11
English: Dementia-related psychosis and/or behavioural disturbances
Estonian: Maksa- ja sapiteede häired
English: Yellow coloured circular flat bevelled edge with ‘OL' debossed on one side and ‘F' debossed on other side.
Estonian: Kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „OL” ja teisele küljele on pressitud „F”.
English: No long-term outcome is available.
Estonian: Pikaajalised tulemused ei ole kättesaadavad.
English: If you have not used it within 3 hours, throw it away.
Estonian: Kui te ei ole seda 3 tunni jooksul kasutanud, visake see ära.
English: SE-11276 Stockholm Sweden
Estonian: SE-11276 Stockholm Rootsi
English: Date of first authorisation: 13 April 1999 Date of latest renewal: 15 April 2014
Estonian: Müügiloa esmase väljastamise kuupäev: 13. aprill 1999 Müügiloa viimase uuendamise kuupäev: 15. aprill 2014
English: This is of importance particularly when changing the laboratory and/or reagents used.
Estonian: See on eriti oluline labori ja/või kasutatavate reaktiivide vahetamisel.
English: It is important that the recommendations in section 6.3 be followed closely.
Estonian: Kindlasti tuleb rangelt järgida lõigus 6.3 toodud soovitusi.
English: Repeat every 12-24 hours.
Estonian: Korrata iga 12...24 tunni järel.
English: Chemical and physical in-use stability has been demonstrated for 3 hours at temperatures up to 25°C.
Estonian: Keemilist ja füüsikalist stabiilsust kasutamisel on tõestatud 3 tunni jooksul temperatuuril kuni 25 °C.
English: Other medicines and ReFacto AF
Estonian: Muud ravimid ja ReFacto AF
English: Do not attempt self-infusion unless properly trained.
Estonian: Ärge püüdke endale ise infundeerida, kui te ei ole saanud piisavat väljaõpet.
English: Date removed from the refrigerator:
Estonian: Külmkapist väljavõtmise kuupäev: